VIETNAM · PHARMA · MARKET ANALYSIS

Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

Vietnam's pharma market enters 2027 anchored on a USD 8.0 bn 2025 base trending to USD 12.0 bn by 2030. Decision 1165 sets the domestic-supply policy floor at 80% volume / 70% value by 2030, and Circular 40/2025/TT-BYT now rewards EU-GMP-certified local production in hospital tenders. The biosimilar wave — Celltrion's Remsima and Herzuma already launched; Nanogen's Stimus in late-stage trials — opens the second margin leg.

Executive summary

Vietnam's pharmaceutical market is valued at approximately $7.5 billion in 2025, growing at 11% CAGR driven by ageing demographics, rising chronic disease prevalence, expanding National Health Insurance (BHYT) coverage (currently 93% of population), and increasing healthcare spending as incomes rise. Domestic pharmaceutical manufacturers — Dược Hậu Giang, Imexpharm, Pymepharco — supply approximately 50% of the market by volume but primarily in generic formulations and OTC products. Imported branded pharmaceuticals from Europe, US, Japan, and Korea dominate the hospital tender and high-value prescription segments. Vietnam's pharmaceutical regulatory authority (DAV) is implementing WHO-GMP certification requirements that are driving consolidation among domestic manufacturers and attracting FDI in compliant manufacturing. This report covers Vietnam's pharmaceutical market by segment and distribution channel, BHYT reimbursement dynamics, domestic versus imported brand dynamics, regulatory modernisation timeline, hospital tender market structure, and the market growth outlook through 2027.

Report details

Published
2026-05-26
Pages
26
Format
PDF
Code
VN-PHA-XPL-D27-01
Market
Vietnam
Industry
Pharma
Year
2026

Table of contents · 11 sections

  1. 01 Methodology
  2. 02 Contents
  3. 03 Executive summary
  4. 04 Macro & policy backbone
  5. 05 Market sizing & channel split
  6. 06 Localization & the EU-GMP race
  7. 07 Competitive landscape
  8. 08 Biosimilar adoption
  9. 09 Regulatory & tender system
  10. 10 5-year outlook & forecast
  11. 11 Methodology endnote

The full report is available to subscribers and buyers. The executive summary above is free to read.

Key questions

What share of Vietnam's drug market is tender-driven ETC?

The tender-driven ETC channel accounts for about 75% of Vietnam's drug market value in 2025, according to KIRA's 2026 market report (Stellapharm 2025).

Source: Stellapharm 2025, 2025 · KIRA report: Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

How much of Vietnam's drug market value does the pharmacy channel drive?

The pharmacy channel drives 61% of market value and grew 11% in H1 2025, according to KIRA's 2026 market report (VIRAC 2025).

Source: VIRAC 2025, 2025 · KIRA report: Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

How much of Imexpharm in Vietnam does SK Group own?

SK Group holds about 48% of Imexpharm, according to KIRA's 2026 market report (VIR 2024).

Source: VIR 2024, 2024 · KIRA report: Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

How big is Vietnam's drug market?

Vietnam's drug market was about USD 8.0 bn in 2025, growing about 7% a year to 2030, according to KIRA's 2026 market report (Fortune BI 2025).

Source: Fortune BI 2025, 2025 · KIRA report: Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

What share of hospital tender value goes to domestic suppliers in Vietnam?

Domestic suppliers held 26.2% of hospital tender value on a VND 34.7tn 2023 base, according to KIRA's 2026 market report (VSS 2024).

Source: VSS 2024, 2023 · KIRA report: Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

How much cheaper are biosimilars than reference biologics in Vietnam?

Biosimilars trade at 50-70% ASP discounts to reference biologics, according to KIRA's 2026 market report (InsightAce 2025).

Source: InsightAce 2025 · KIRA report: Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

What is Decision 1165's domestic target for Vietnam's drug market?

Decision 1165 targets domestic drugs at 70% of market value by 2030, according to KIRA's 2026 market report (Decision 1165 2023).

Source: Decision 1165 2023, 2030 · KIRA report: Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

How many plants in Vietnam hold EU-GMP certification?

Only 17 plants nationally hold EU-GMP certification, according to KIRA's 2026 market report (InvestVietnam 2025).

Source: InvestVietnam 2025 · KIRA report: Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

How dependent is Vietnam on imported APIs?

Local production covers only a fraction of Vietnam's API needs, with import dependency above 80%, according to KIRA's 2026 market report (Kira estimates based on Davipharm + EuroCham 2024).

Source: Kira estimates based on Davipharm + EuroCham 2024, 2024 · KIRA report: Vietnam pharma 2027 outlook: generics localization and biosimilar adoption

More on Pharmaceuticals in Vietnam